A dual labelling method for measuring uptake of low molecular weight compounds into the pathogenic yeast Candida albicans

Medical Mycology

Volumn 36, Issue 5, 1998, Pages 323-330

  Ziegelbauer, Karl ^a,b  

^a BAYER AG   (Germany)

^b BAYER YAKUHIN LTD   (Japan)

Author keywords

Candida albicans; Membrane; Permeability; Resistance; Uptake

Indexed keywords

CARBON 14; TRITIUM OXIDE;

ARTICLE; CANDIDA ALBICANS; CELL WALL; MEMBRANE PERMEABILITY; NONHUMAN; SPHEROPLAST; SUPERNATANT;

CANDIDA ALBICANS; EUKARYOTA; TRITIUM;

EID: 33746421436     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-280X.1998.00167.x     Document Type: Article

References (44)

1. Perfect JR. Fungal infections. Curr Opin Inject Dis 1992; 5: 433-6.
2. Georgopapadakou NH, Walsh TJ. Human mycoses: drugs and targets for emerging pathogens. Science 1994; 264: 371-3.
3. Beck-Sague CM, Jarvis WR, and the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-1990. J Infect Dis 1993; 167: 1247-51.
4. Fisher-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995; 21: 897-904.
5. Fridkin SK. Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511.
6. Pfaller MA, Wenzel RP. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992; 11: 287-91.
7. Pfaller MA. Epidemiology of candidiasis. J Hosp Infect 1995; 30 (suppl): 329-38.
8. Odds F. Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects. Int J Antimicrob Agents 1996; 6: 141-4.
9. Herreros E, Garcia-Saez MI, Nombela C, Sanchez MA. A reorganized Candida albicans DNA sequence promoting homologous non-integrative genetic transformation. Mol Microbiol 1992; 6: 3567-74.
10. Dehoux P, Davies J, Cannon M. Natural cycloheximide resistance in yeast. The role of ribosomal protein L41. Eur J Biochem 1993; 213: 841-8.
11. Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother 1980; 18: 158-63.
12. Kawai S, Murao S, Mochizuki M, Shibuya I, Yano K, Takgi M. Drastic alteration of cycloheximide sensitivity by substitution of one amino acid in the L41 ribosomal protein of yeasts. J Bacteriol 1992; 174: 254-62.
13. Balzi E, Wang M, Leterme S, Van Dyck L, Goffeau A. PDR5 a novel yeast multidrug resistance conferring transporter controlled by the transcription regulator PDR1. J Biol Chem 1994; 269: 2206-14.
14. Bissinger PH, Kuchler K. Molecular cloning and expression of the Saccharomyces cerevisiae STS1 gene product. A yeast ABC transporter conferring mycotoxin resistance. J Biol Chem 1994; 269: 4180-6.
15. Nishi K, Yoshida M, Nishimura M, et al. A leptomycin B resistance gene of Schizosaccharomyces pombe encodes a protein similar to the mammalian P-glycoproteins. Mol Microbiol 1992; 6: 761-9.
16. Prasad R, Dewergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans CDR1 conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320-9.
17. Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300-5.
18. Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2 a new multidrug ABC transporter gene. Microbiology 1997; 143:405-16.
19. Ben-Yaacov R, Knoller S. Caldwell GA, Becker JM, Koltin Y. Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Animicrob Agents Chemother 1994; 38: 648-52.
20. Fling ME, Kopf J, Tamarkin A, German JA, Smith HA, Koltin Y. Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 1991; 227: 318-29.
21. Jai Z-P, McCullough L, Wong L, Young PG. The amiloride resistance gene carl of Schizosaccharomyces pombe. Mol Gen Genet 1993; 241: 298-304.
22. Kanazawa S, Driscoll M, Struhl K. ATR1 a Saccharomyces cerevisiae gene encoding a transmembrane protein required for aminotriazole resistance. Mol Cell Biol 1988; 8: 664-73.
23. Sasnauskas K, Jomantiene R, Lebediene E, Lebedys J, Januska A, Janulaitis A. Cloning and sequence analysis of a Candida maltosa gene which confers resistance to cycloheximide. Gene 1992; 116: 105-8.
24. Decottignies A, Kolackowski M, Balzi E, Goffeau A. Solubilization and characterization of the overexpressed PDR5 multidrug resistance nucleotide triphosphatase of yeast. J Biol Chem 1994; 269: 12797-803.
25. Alarco AM, Balan I, Talibi D, Mainville N, Raymond M. AP1-mediated multidrug resistance in Saccharomyces cerevisiae requires FLR1 encoding a transporter of the major facilitator superfamily. J Biol Chem 1997; 272: 19304-13.
26. Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6: 1-21.
27. Odds FC. Candida and Candidosis. London: WB Saunders, 1988.
28. Nobel JG, Barnett JA. Passage of molecules through yeast cell walls: a brief essay-review. Yeast 1991; 7: 313-23.
29. Poulain D, Cailliez JC, Dubremetz JF. Secretion of glycoproteins through the cell wall of Candida albicans. Eur J Cell Biol 1989; 50: 94-9.
30. Gale EF. Nature and development of phenotypic resistance to amphotericin B in Candida albicans. Adv Microb Physiol 1986; 27: 278-321.
31. Hitchcock CA, Russell NJ, Barrett-Bee KJ. Sterols in Candida albicans mutants resistant to polyene or azole antifungals and of a double mutant C. albicans 64. Crit Rev Microbiol 1987; 15: 111-5.
32. Hitchcock CA, Pye GW, Troke PF, Johnson EM, Warnock DW. Fluconazole resistance in Candida glabrata. Antimicrob Agents Chemother 1993; 37: 1962-5.
33. Odds FC. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother 1993; 31: 463-71.
34. Hemmi K, Julmanop C, Hirata D, Tsuchiya E, Takemoto JY, Miyakawa T. The physiological roles of membrane ergosterol as revealed by the phenotypes of syr1/erg3 null mutant of Saccharomyces cerevisiae. Biosci Biotech Biochem 1995; 59: 482-6.
35. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-86.
36. Rottenberg H. The measurement of membrane potential and delta pH in cells organelles and vesicles. Meth Enzymol 1979; 55: 547-69.
37. Prasad R. Nutrient transport in Candida albicans a pathogenic yeast. Yeast 1987; 3: 209-21.
38. Nikado H, Thanassi DG. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 1993; 37: 1393-9.
39. Davis R, Markham A, Balfour JA. Ciprofloxacin, an updated review of its pharmacology therapeutic efficacy and tolerability. Drugs 1996; 51: 1019-74.
40. Pleiss U. Conrad M, Baasner B. Synthesis of N-(4-(2-(24-Dimethylphenoxy)phenyl)-2-thiazolyl)-hexahydro-2-pyrimidinimine 14C) BAY w 6341. J Label Comp Radiopharmal 1995; 36: 275-9.
41. Schaller K, Itayama H, Tiemann R, Uchida K, Yamaguchi H. Bay w 6341, a novel broad spectrum fungicidal agent impairs cell membrane function of Candida albicans. XIITH Congress of the International Society of Human And Animal Mycology (ISHAM), Adelaide, 1994.
42. Vry J, Dietrich H, Glaser T, et al. BAY x3702 neuroprotectant (5-HT1A) agonist. Drugs Fut 1997; 22: 341-9.
43. Abram TS, Boshagen H, Butler JE, et al. New structural analogue antagonist of peptido-leukotrienes. The discovery of BAY x7195. Bioorg Med Chem Lett 1993; 3: 1517-22.
44. Ziegelbauer K, Babcziuski P, Schonfeld W. Molecular mode of action of the antifungal β-amino acid BAY 10-8888. Antimicrob Agents Chemother 1998; in press.